leisure time -WSS

leisure time

author：leisure time 2025-09-28 02:47:52 - browse：181

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Heart attack and stroke risk calculators need revising
Next article： FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

WSS

Thermo Fisher plant for manufacturing gene therapies to expand

Readers discuss the intersection of pregnancy and addiction

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

EpiPen alternative approval delay highlights citizen petition issue

How AI helped researchers track recovery from depression

Drug for rare kidney disease narrowly misses mark in clinical trial

focus

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

Apple is now the first public company to be valued at $3 trillion

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Hepatitis C has a cure — but many Americans still lack access to it

Biotech stock slump in 2023: awaiting the turnaround

Duchenne breakthrough therapy leaves behind pioneering families

Senators: Long

23andMe had bad news about my health. I wish a person had delivered it

Study: Why relieving medical debt did not improve financial outcomes

Dobbs anniversary: the lost opportunity of abortion as health care

Moderna says combo Covid

focus

Coercive sterilizations revealed by STAT prompt outrage

Experts study whether long Covid risk adds up with each reinfection

Experts study whether long Covid risk adds up with each reinfection

Intarcia’s device

My daughter's legacy lives on through her writing, phage therapy

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

focus

hotspot

focus

knowledge